Group 1 - The core point of the article is that Tianyao Pharmaceutical reported a total of 38,337 shareholders as of January 30, 2026 [2]

Summary of Key Points Core Viewpoint - Tianyao Pharmaceutical (600488) is facing regulatory scrutiny due to violations related to information disclosure and internal control issues, which may impact investor confidence and operational integrity [1][3]. Trading Information - As of January 29, 2026, Tianyao Pharmaceutical's stock closed at 4.2 yuan, down 1.64%, with a turnover rate of 1.15%, a trading volume of 125,400 shares, and a transaction value of 52.7973 million yuan [1]. Capital Flow - On January 29, 2026, the net outflow of main funds was 1.475 million yuan, accounting for 2.79% of the total transaction value; retail investors experienced a net outflow of 404,800 yuan, representing 0.77% of the total transaction value, while speculative funds saw a net inflow of 1.8798 million yuan, making up 3.56% of the total transaction value [1][3]. Regulatory Penalties - On January 28, 2026, Tianyao Pharmaceutical and several executives were ordered to rectify their actions by the Tianjin Securities Regulatory Bureau due to violations of securities laws and regulations, including failure to disclose significant events in a timely manner [1][3]. Company Announcements - On January 27, 2026, Tianyao Pharmaceutical received an administrative regulatory measure decision from the Tianjin Securities Regulatory Bureau, citing issues with non-compliant contracts for technology projects and failure to timely identify risks related to R&D project terminations, which led to delays in the recovery of advance payments [1][3].

Core Viewpoint - The company, Tianjin Pharmaceutical Industry (津药药业), is committed to implementing effective measures for rectification in accordance with relevant laws and regulations, aiming to enhance its operational standards and promote healthy and stable development [1] Group 1 - The company has responded to investor inquiries on an interactive platform, indicating its intention to strictly adhere to regulatory requirements [1] - The administrative regulatory measures will not affect the company's normal business operations [1] - The company emphasizes its focus on improving compliance and operational standards [1]

Core Viewpoint - Recently, Tianjin Pharmaceutical Industry announced that it received an administrative regulatory decision from the Tianjin Regulatory Bureau of the China Securities Regulatory Commission on January 27, 2026, due to issues related to non-compliance in external technology project contracts and failure to timely identify risks associated with the termination of R&D projects, leading to delays in the recovery of advance payments [1] Group 1 - The company has been found to have non-compliant contracts for certain externally purchased technology projects [1] - There was a failure to timely recognize the risks associated with the termination of R&D projects, which resulted in delays in the recovery of advance payments [1] - The decision letter indicates that the former chairman and general manager Wang Fujun, former general manager Zhang Jie, current chairman Xu Hua, and current general manager Li Shuxiang bear primary responsibility for the issues identified [1] Group 2 - The regulatory bureau has decided to implement corrective supervisory measures against the company [1] - Warning letters have been issued to the responsible personnel regarding the identified issues [1]

Core Viewpoint - The management changes at Tianyao Pharmaceutical (600488) are described as normal operational adjustments, with the company confirming that its production and business operations are proceeding normally and in an orderly manner [1]. Group 1 - The company has responded to investor inquiries regarding recent management changes [1] - The management changes are characterized as standard work adjustments [1] - The company assures that its production and operational status is normal [1]

1月28日，津药药业（SH600488，股价4.27元，市值46.62亿元）发布公告称，公司于1月27日收到中国 证券监督管理委员会天津监管局（以下简称"天津证监局"）下发的《行政监管措施决定书》，因合同管 理不规范、研发项目风险识别不足等，公司被责令改正，5名现任及前任高管被出具警示函。 津药药业作为以甾体激素、氨基酸原料药及制剂为主营业务的企业，外购技术和研发投入是其核心竞争 力的重要来源，若相关环节管理失当，不仅可能导致经济损失，还可能影响产品研发进度和市场竞争 力。 事实上，津药药业的合规问题也正与业绩下滑形成共振。 这一监管措施再次将公司的合规问题推向公众视野。值得关注的是，津药药业近年来业绩持续承压， 2025年前三季度，公司归母净利润同比下降62.75%，其中反垄断行政处罚等合规成本对利润形成显著 拖累。公司被责令改正，5名责任人被出具警示函 2025年前三季度，公司实现营收22.32亿元，同比下降13.24%；归母净利润为6954万元，同比下降 62.75%。业绩下滑主因包括集采压价、终端用药需求减少及国际竞争加剧导致销售单价下滑、毛利收 缩，而上述高达6919万元的反垄断罚款，进一步加剧了利 ...

上交所决定，对津药药业股份有限公司及现任董事长徐华、总经理李书箱，时任董事长兼总经理王福 军、张杰，时任总经理杨福祯予以监管警示。 1月28日，上交所发布关于对津药药业股份有限公司及有关责任人予以监管警示的决定。经查，公司存 在以下违规情形：一是部分外购项目采用制式合同，合同对违约责任的约定不够明确，关于外购项目合 同违约责任等关键条款的信息披露不完整；二是未能及时识别部分研发项目的终止风险，部分研发项目 已终止但未及时履行信息披露义务。责任人方面，公司现任董事长徐华、时任董事长王福军、张杰作为 公司主要负责人和信息披露第一责任人，现任总经理李书箱、时任总经理杨福祯作为公司经营管理主要 负责人，未能勤勉尽责，对上述违规行为负有责任。 ...

证券代码：600488 证券简称：津药药业 编号：2026-006 津药药业股份有限公司 关于收到天津证监局行政监管措施决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2026 年 1 月 27 日，津药药业股份有限公司（以下简称"公司"） 收到中国证券监督管理委员会天津监管局下发的《行政监管措施决定 书》（津证监措施〔2026〕8 号，以下简称"《决定书》"），现将 相关情况公告如下： 一、《决定书》内容 津药药业股份有限公司、徐华、李书箱、王福军、张杰、杨福祯： 经查，津药药业股份有限公司(以下简称"津药药业"或"公司") 存在以下问题:一是部分外购技术项目采用制式合同，对对方违约责 任的约定不够明确，合同内容不规范。二是未能及时识别部分研发项 目的终止风险，导致预付款收回不及时。公司上述行为违反了《上市 公司治理准则》(证监会公告〔2018〕29 号)第九十四条第一款、《企 业内部控制应用指引第 16 号--合同管理》第六条第一款、《企业内 部控制应用指引第 6 号--资金活动》第三条第四项、第二十条第一款 ...

法律意见书 天津长实律师事务所 关于津药药业股份有限公司 2026 年 长实律见字【2026】01号 天津长实律师事务所 天津市河西区宾水道 11 号宾泰公寓 C-1801 电话：022-28363638 传真：022-28363638 长实律师事务所 ChangshiLaw Firm 第一次临时股东会的 天津长实律师事务所 关于津药药业股份有限公司2026年第一次临时股东会的 法律意见书 长实律见字【2026】01号 致：津药药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》《上市公司股东会规则》等法律、法规和规范性文件以及《津药 药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定，天津长实 律师事务所（以下简称"本所"）接受津药药业股份有限公司（以下简称"贵公 司"）委托，指派律师出席了贵公司召开的2026年第一次临时股东会（以下简称 "本次股东会"）现场会议，并就本次股东会相关事宜出具本法律意见书。 为出具本法律意见书，本所律师对本次股东会所涉及的有关事项进行了审 查，并查阅了贵公司提供的有关召开本次股东会相关文件的原件或影印件，包括 但不限于 ...

证券代码：600488 证券简称：津药药业 公告编号：2026-005 津药药业股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 201 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 637,243,020 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 58.3616 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由公司董事会召集，公司董事长徐华先生主持，采取现场记名投 票和网络投票相结合的表决方式。会议召集、召开程序符合《中华人民共和国公 司法》《公司章程》等的规定。 二、 议案审议情况 表决情况： (一) 股东会召开的时间：2026 年 1 月 26 日 (二) 股东会 ...